New drug shows promise for ARDS patients in major trial
NCT ID NCT04909697
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This clinical trial tested a drug called sivelestat sodium in 324 adults with acute respiratory distress syndrome (ARDS) and systemic inflammation. The drug aims to block a harmful enzyme that damages lung tissue. Researchers measured whether it improved oxygen levels and reduced the need for a breathing machine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sivelestat sodium
- What this could lead to
- If it works, this could provide a new treatment option for ARDS patients, potentially improving oxygen levels and reducing time on a ventilator.
- What could go wrong
- This is a completed Phase 4 trial, but results are not yet widely reported. The drug may not show significant benefit over standard care, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sichuan provincial people's hospital
Chengdu, Sichuan Privince, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Lung-Opening maneuver change a key injury marker in ARDS?
- Could simply sitting up ease breathing in severe lung failure?
- Could lung fluid proteins reveal a new way to track severe lung injury?
- Could a spirometer test guide breathing support in respiratory failure?
- Which ventilator setting saves more lungs? a Head-to-Head test
- Can a single antibody turn down the immune storm in ARDS?